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Abstract
We previously demonstrated that unconjugated bilirubin spontaneously diffuses through phospholipid bilayers at a rate
which exceeds albumin dissociation, suggesting that solvation from albumin represents the rate-limiting step in hepatic
bilirubin clearance. To further examine this hypothesis, we studied the uptake of bovine serum albumin (BSA)-bound
bilirubin by cultured hepatoblastoma (HepG2) cells. Uptake of bilirubin was saturable, with a Km and Vmax of 4.2 þ 0.5 WM
( þ S.E.M.) and 469 þ 41 pmol min31 mg31 at 25‡C. Substantial bilirubin uptake also was observed at 4‡C (Km = 7.0 þ 0.8
WM, Vmax = 282 þ 26 pmol min31 mg31), supporting a diffusional transport mechanism. Consistent with reported solvation
rates, the cellular uptake of bilirubin bound to human serum albumin was more rapid than for BSA-bound bilirubin,
indicative of dissociation-limited uptake. Counterintuitively, an inverse correlation between pH and the rate of bilirubin flip-
flop was observed, due to pH effects on the rate of dissociation of bilirubin from albumin and from the membrane bilayer.
The identification of an inflection point at pH 8.1 is indicative of a pKa value for bilirubin in this range. Taken together, our
data suggest that hepatocellular uptake of bilirubin is dissociation-limited and occurs principally by a mechanism involving
spontaneous transmembrane diffusion. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Bilirubin IXK, the hydrophobic product of heme
catabolism, is e⁄ciently metabolized by the liver and
secreted into bile as the water-soluble diglucuronide.
The clearance of bilirubin by the liver is saturable
and occurs against a concentration gradient [1^3],
¢ndings which support protein-mediated bilirubin
transport across the basolateral (sinusoidal) mem-
brane of the hepatocyte. Several putative bilirubin
transporters have been identi¢ed and isolated [4^6]
although none has yet been cloned or shown to spe-
ci¢cally transport unconjugated bilirubin (UCB). Al-
ternatively, it has been postulated that hepatocellular
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bilirubin uptake occurs by spontaneous di¡usion
through the plasma membrane [7^10]. In support of
this hypothesis, we have recently demonstrated that
UCB di¡uses rapidly through model and isolated
native hepatocyte membrane vesicles via a mecha-
nism involving £ip-£op of the diacid species [11].
Based on an extension of the Bass-Pond di¡usion
model [12], Weisiger has proposed that hepatic up-
take of certain ligands may be limited by dissociation
from plasma binding proteins [13]. Our ¢nding that
the rate of bilirubin transmembrane di¡usion exceeds
the o¡-rate from serum albumin [14] led to the prop-
osition that solvation from serum albumin represents
the rate-limiting step in the clearance of UCB by the
liver [11]. Indirect experimental evidence supporting
dissociation-limited bilirubin transport is derived
from studies demonstrating that uptake of bovine
serum albumin (BSA)-bound bilirubin by the iso-
lated, perfused rat liver is signi¢cantly slower than
uptake of bilirubin solubilized in Fluosol-43 (in the
absence of binding proteins) or bilirubin bound to
ligandin [2], from which bilirubin dissociation is
more rapid as compared with BSA [14,15]. Addition-
ally, analbuminemic Nagase rats exhibit an enhanced
rate of bilirubin clearance when compared with con-
trol animals possessing normal serum albumin levels
[16].
While there have been a host of studies character-
izing the transport and clearance of UCB in intact
animals [1,17,18], in the perfused liver [2,3,18,19],
and in isolated plasma membrane vesicles [11,20]
there is a surprising paucity of information regarding
bilirubin uptake at the cellular level. Iga et al. [21]
found the uptake of UCB by cultured rat hepato-
cytes to be non-saturable and concluded that biliru-
bin transport occurs by transmembrane di¡usion.
However, these studies were performed in the ab-
sence of a protein carrier, and utilized bilirubin con-
centrations far in excess of the aqueous solubility.
While other investigators have demonstrated uptake
of UCB by cultured hepatocytes [4] and HepG2 cells
[6] in the presence of albumin, kinetic analyses were
not performed. In the present studies, we conduct
cellular uptake analyses and utilize stopped-£ow
£uorescence techniques in order to determine biliru-
bin uptake kinetics and further characterize the
mechanism(s) underlying the hepatocellular transport
of UCB.
2. Materials and methods
2.1. Materials
Nigericin and essentially fatty acid-free bovine and
human serum albumin were purchased from Sigma
Chemical Company (St. Louis, MO). Bilirubin IXK
was obtained from Porphyrin Products (Logan, UT),
with purity (s 99.5%) assessed by absorbance in
chloroform [10]. Grade 1 egg lecithin (phosphatidyl-
choline) was purchased from Lipid Products (Surrey,
UK). Cascade blue-conjugated bovine serum albu-
min (cbBSA) and anti-Cascade blue antibodies were
obtained from Molecular Probes (Eugene, OR). N-
(5-Dimethylaminonaphthalene-1-sulfonyl) dipalmito-
yl-L-K-phosphatidylethanolamine (dansyl-PE) was
purchased from Avanti Polar Lipids (Birmingham,
AL), and N-[3,5-3H]aminolevulinic acid from NEN
Life Sciences (Boston, MA).
2.2. In vivo synthesis of radiolabeled bilirubin
[3H]Bilirubin IXK was prepared by intravenous in-
fusion of the metabolic precursor, N-[3,5-3H]amino-
levulinic acid (250 WCi), into anesthetized male
Sprague-Dawley rats (Charles River Breeding Labo-
ratories, Wilmington, MA). Bile was collected for 6 h
and bilirubin isolated by hydrolysis of glucuronides,
precipitation with lead acetate, and extraction in
chloroform [22,23]. Prepared in this manner, biliru-
bin speci¢c activity ranged from 0.05 to 0.10 WCi
nmol31, with purity assessed at over 98% by absor-
bance in chloroform solution. All steps were carried
out in the dark to minimize bilirubin photodegrada-
tion.
2.3. Measurement of bilirubin uptake by HepG2 cells
Human hepatoblastoma (HepG2) cells were grown
in Dulbecco’s modi¢ed Eagle’s medium supple-
mented with 10% fetal bovine serum, 1% non-essen-
tial amino acids, and 1% L-glutamine under 5% CO2
to contain 2U106 cells per 35 mm dish (V70% con-
£uent). Prior to uptake experiments, monolayers
were washed repeatedly with phosphate-bu¡ered sa-
line (PBS) to remove residual albumin. The cells were
then incubated at either 25‡C or 4‡C in PBS contain-
ing [3H]bilirubin (1^2U105 dpm) bound either to
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bovine or human serum albumin. At various time
intervals, the medium was rapidly removed and the
cells washed twice with ice-cold PBS, followed by an
additional wash with ice-cold PBS containing 5%
BSA in order to completely displace surface-associ-
ated bilirubin. Further washes (with or without albu-
min) had no additional e¡ect on cell associated ra-
dioactivity. Cells were dispersed with 0.1 M NaOH
and counted in 20 ml of ScintiVerse II (Sigma Chem-
ical Company). The quantity of bilirubin taken up
by the cells was never more than 3% of the total
added (1^6U103 dpm per data point), ensuring that
no signi¢cant depletion of bilirubin from the medium
occurred over the time course of the experiments.
Replicate plates were harvested for protein deter-
mination, using the assay method of Lowry et al.
[24].
2.4. A⁄nity of human and bovine serum albumin for
bilirubin
The relative a⁄nity of human (HSA) and bovine
serum albumin (BSA) for UCB was determined from
the equilibrium binding. Partitioning was quanti¢ed
by recording the steady-state £uorescence of bilirubin
(ex: 467 nm, em: 525 nm) in the presence of varying
molar ratios of the proteins, and ¢tting the data to
the equation:
IHSA3IBSA
Iobs3IBSA
 1 K
BSA
a
KHSAa
  BSA
HSA
 
1
where IHSA and IBSA represent the £uorescence inten-
sity of bilirubin in the presence of HSA or BSA
alone, Iobs re£ects bilirubin £uorescence intensity at
a de¢ned molar ratio of BSA:HSA, Ka the associa-
tion constant, and [BSA] and [HSA] the concentra-
tions of bovine and human serum albumin, respec-
tively. As the £uorescence intensity of bilirubin is
dependent on the albumin species to which it is
bound, the slope of a plot of (IHSA3IBSA)/
(Iobs3IBSA) versus the molar ratio of BSA:HSA pro-
vides a direct measure of the relative a⁄nity for bi-
lirubin (KBSAa /K
HSA
a ). The total albumin concentra-
tion ([HSA]+[BSA]) was maintained constant in
order to control for inner ¢lter e¡ects resulting
from intrinsic protein absorbance.
2.5. Isolation of white erythrocyte ghosts
Erythrocyte plasma membranes (ghosts) were iso-
lated from 30 ml of human blood obtained from
healthy volunteers, using a modi¢cation [25] of the
method of Steck et al. [26]. The phlebotomy protocol
and consent procedure were approved by the Brig-
ham and Women’s Hospital Human Research Com-
mittee (Protocol #96-07907). White (hemoglobin-de-
plete) erythrocyte ghosts were prepared in order to
avoid potential competition between bilirubin and
hemoglobin for binding to albumin [27]. No detect-
able hemoglobin was present in the preparation, as
measured by the assay method of Riggs [28].
2.6. Preparation of small unilamellar phospholipid
vesicles
Small unilamellar vesicles were prepared by probe
sonication, as previously described [10]. A chloro-
form solution of phosphatidylcholine was evaporated
to dryness under argon atmosphere, solubilized in
ether, and re-evaporated to form a uniform ¢lm.
The dried lipids were suspended in 0.1 M potassium
phosphate solution and sonicated until clear. The
vesicle suspension was centrifuged in order to sedi-
ment probe titanium particles and large vesicle con-
taminants, and the phospholipid concentration quan-
ti¢ed by the assay method of Bartlett [29].
Fluorescent-labeled vesicles were prepared by incor-
porating dansyl-PE (0.5 mol%) at the time of soni-
cation [10].
2.7. Stopped-£ow analysis of bilirubin transmembrane
di¡usion
The rate of bilirubin transmembrane di¡usion was
determined from the time-dependent £uorescence
changes associated with bilirubin equilibration be-
tween a suspension of small unilamellar phosphati-
dylcholine vesicles and cbBSA, as previously de-
scribed [11]. UCB was incorporated into
phospholipid vesicles by ¢rst dissolving bilirubin in
alkaline (pH 12.0) potassium phosphate [10] and sub-
sequently adding the solubilized bilirubin to small
unilamellar phosphatidylcholine vesicles suspended
in 0.1 M potassium phosphate bu¡ered at pH 7.4
(unless otherwise indicated). The addition of a small
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aliquot (9 1% v:v) of the bilirubin stock solution to
the vesicle suspension caused no detectable alteration
in the pH of the medium. An Aminco-Bowman II
£uorescence spectrophotometer equipped with an
SLM-Aminco MilliFlow stopped-£ow reactor facili-
tated the rapid mixing of the bilirubin-containing
vesicles with an equal volume of cbBSA solubilized
in 0.1 M potassium phosphate. Bilirubin quenches
cbBSA £uorescence (excitation: 380 nm, emission:
430 nm) in a concentration-dependent manner, such
that the time-dependent diminution in Cascade blue
£uorescence intensity re£ects the combined process
of bilirubin £ip-£op from the internal to the external
hemilea£et of the bilayer and subsequent dissociation
and transfer from the external surface of the donor
vesicles to cbBSA.
In order to speci¢cally examine the process of
bilirubin transmembrane £ip-£op, data points were
obtained every 200 ms [11] and the time course
for bilirubin equilibration was analyzed by ¢tting
the £uorescence curves to the function: F(t) =
gAiexp(3kit)+C, where t is time, ki the ith-order
rate constant, Ai the amplitude, and C a constant
term. Quality of ¢t was assessed by regression anal-
ysis, and an F-test applied to determine if the inclu-
sion of an additional term provided a statistically
signi¢cant improvement in curve ¢t [10]. As previ-
ously shown [11], the measured rate of equilibration
(R) is dependent on the molar ratio of phospho-
lipid:cbBSA:
R 
KBSAa
KPLa
 PLBSA
KBSAa
KPLa
1
kff
 
 PLBSA
1
kBSAoff
 ! 2
where Ka represents the a⁄nity constant, koff the
dissociation rate constant, kff the £ip-£op rate con-
stant, and [BSA] and [PL] the concentrations of
cbBSA and vesicle phospholipid, respectively. From
Eq. 2 it is apparent that a plot of R versus [PL]/
[BSA] intersects the y-axis at the £ip-£op rate con-
stant (kff ), and asymptotically approaches the biliru-
bin dissociation rate constant from cbBSA (kBSAoff ) at
high molar ratios of phospholipid:cbBSA.
The rate of solvation of UCB from phospholipid
vesicles was determined from the £uorescence record-
ings of bilirubin equilibration between a suspension
of 0.5 mol% dansyl-PE-labeled small unilamellar
phosphatidylcholine donor vesicles and unlabeled ac-
ceptor vesicles, as previously described [10]. The
binding of bilirubin to dansyl-labeled vesicles causes
a reduction in £uorescence intensity due to resonance
energy transfer between bilirubin and the dansyl moi-
ety. The reemergence of dansyl £uorescence (excita-
tion: 340 nm, emission: 525 nm) that occurs follow-
ing the rapid mixing of the two vesicle populations
re£ects bilirubin transfer from the donor to the ac-
ceptor membranes. Due to the rapid rate of bilirubin
solvation from phospholipid vesicles at pH 7.4 [10],
analysis of bilirubin-membrane dissociation was per-
formed with an Applied Photophysics (Leatherhead,
UK) £uorescence spectrophotometer equipped with
an SPF-17 stopped-£ow device (mixing time: 0.7 ms).
3. Results
We have previously shown that the o¡-rate for
UCB from human serum albumin is approximately
¢ve times slower than spontaneous transmembrane
di¡usion [11,14], suggesting that solvation from al-
bumin represents the rate-limiting step in the hepa-
tocellular clearance of bilirubin. To test this hypoth-
esis, we examined the uptake of UCB by human
hepatoblastoma (HepG2) cells, as this cell line has
previously been shown to take up both bromosul-
fophthalein (BSP), a commonly used bilirubin surro-
gate, and bilirubin diglucuronide [6]. Human and
bovine serum albumins were utilized as the bilirubin
donor in these studies because of high-a⁄nity bind-
ing and a nearly 10-fold di¡erence in bilirubin disso-
ciation rate [14].
3.1. Bilirubin uptake by HepG2 cells
Uptake studies were performed by incubating
HepG2 monolayers in the presence of HSA- or
BSA-bound [3H]bilirubin IXK. At various time inter-
vals, the medium was aspirated and the cells were
washed, harvested, and counted. Bilirubin uptake at
25‡C was rapid (Fig. 1), with a ¢rst-order rate con-
stant of 0.27 þ 0.15 s31 ( þ S.E.M.) for HSA-bound
and 0.11 þ 0.01 s31 for BSA-bound bilirubin. The
measured uptake rate is unlikely to re£ect cellular
conjugation of bilirubin, which occurs over a more
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protracted time course [30]. The 2.5-fold faster up-
take of human versus bovine serum albumin-bound
bilirubin cannot be explained by higher concentra-
tions of free bilirubin in the presence of HSA, since
this protein has a greater a⁄nity for bilirubin than
does BSA (Fig. 2). Indeed, when BSA serves as the
carrier protein, total cellular uptake of bilirubin ex-
ceeds that observed with HSA (Fig. 1). The ¢nding
that the rate of cellular uptake is determined by the
carrier protein to which bilirubin is bound is consis-
tent with the concept of dissociation-limited trans-
port [13].
Further evidence that bilirubin uptake is dissocia-
tion-limited is derived from the observation that the
rate constant obtained for the uptake of BSA-bound
bilirubin by HepG2 cells correlates closely with the
previously reported o¡-rate for UCB from bovine
serum albumin [14]. In contrast, the measured uptake
rate for HSA-bound bilirubin is approximately three-
fold slower than predicted from the dissociation rate
constant [14]. We believe that this discrepancy re-
£ects the limitations of the experimental system uti-
lized in our uptake studies, in that the earliest time
point at which data can reliably be obtained is 8 s.
As the half-time for bilirubin dissociation from BSA
is V7 s [14], the elapsed time interval before the ¢rst
data point is acquired represents a single half-time.
However, in the case of bilirubin solvation from
HSA (t1=2 = 750 ms), over 10 half-times elapse before
the ¢rst data point is obtained. As a result of these
technical limitations (which also hampered the deter-
mination of uptake at 37‡C), we believe that the
measured 25‡C rate constant underestimates the ac-
tual rate of bilirubin uptake from HSA.
Substantial cellular transport of bilirubin also was
detectable at 4‡C (Fig. 1), with total uptake repre-
senting approximately 65% of that occurring at 25‡C.
The rate constants for the uptake of HSA-bound
(0.20 þ 0.01 s31) and BSA-bound (0.026 þ 0.011 s31)
bilirubin at 4‡C correlate closely with bilirubin o¡-
rates from the respective albumin species at this tem-
perature [14]. This nearly eight-fold di¡erence in up-
take rate further supports that bilirubin transport is
limited by dissociation from the albumin carrier. In-
deed, the free energy of activation (18.8 kcal mol31)
calculated [10] from the temperature dependence of
the cellular uptake rate for BSA-bound bilirubin is
Fig. 2. Binding distribution of bilirubin between human and bo-
vine serum albumin. The equilibrium distribution of UCB (2
WM) between human (HSA) and bovine (BSA) serum albumin
was determined by measuring bilirubin steady-state £uorescence
in the presence of varying molar ratios of HSA:BSA, maintain-
ing the total albumin concentration constant at 16 WM. Each
point, expressed in arbitrary £uorescence units (a.u.), represents
the mean þ S.D. of three separate experiments performed at
25‡C. In the inset, the £uorescence intensity ratio is plotted
against the molar ratio of BSA:HSA. The relative a⁄nity of
the albumin species for bilirubin (KBSAa /K
HSA
a = 0.29 þ 0.005;
þ S.E.M.) is calculated from the slope (r2 = 0.997) of the plot.
Fig. 1. Uptake of UCB by HepG2 cells. Cultured monolayers
of HepG2 cells were incubated in the presence of [3H]bilirubin
IXK (8 WM) bound to human serum albumin (squares) or bo-
vine serum albumin (circles) at a 1:1 molar ratio. Bilirubin up-
take was calculated from the radioactivity present in the cell ly-
sate following exhaustive washing. Data points re£ect the mean
( þ S.D.) of three experiments performed at 25‡C (¢lled sym-
bols) or 4‡C (open symbols) and are ¢t to single exponential
functions (solid lines).
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identical to that for bilirubin dissociation from BSA
[14]. Additionally, the demonstration of signi¢cant
bilirubin uptake at 4‡C is consistent with a non-pro-
tein-mediated (di¡usional) transport mechanism.
We subsequently examined the uptake of UCB by
HepG2 cells over a range of bilirubin concentrations.
In these studies, BSA was utilized as the bilirubin
carrier as the slower uptake rate facilitated the deter-
mination of kinetic parameters. The initial uptake
velocity (V0) was obtained from the linear uptake
of albumin-bound bilirubin over the ¢rst 15 s.
From a double reciprocal plot of the data (Fig. 3),
the Km was calculated to be 4.2 þ 0.5 WM ( þ S.E.M.)
at 25‡C, consistent with physiologic serum bilirubin
concentrations. Moreover, the Vmax of 469 þ 41 pmol
min31 mg31 is similar to hepatocellular uptake rates
reported for other organic anions [6,31]. In order to
determine the kinetic parameters for the uptake of
unbound bilirubin, we calculated the free bilirubin
concentration in these experiments. Using a consen-
sus value for the BSA a⁄nity constant of 2.5U107
M31 [32,33], the concentration of free bilirubin was
less than the reported aqueous solubility of 65 nM
[34] at all but the highest total bilirubin concentra-
tion utilized (18.5 WM). When data points obtained
at this bilirubin concentration are excluded, a double
reciprocal plot of the initial uptake velocity versus
the free bilirubin concentration (Fig. 3, inset) produ-
ces a Km and Vmax at 25‡C of 7.9 þ 1.2 nM and
396 þ 44 pmol min31 mg31, respectively. These re-
sults are highly concordant with the kinetic parame-
ters obtained by investigators examining the uptake
of UCB by rat basolateral plasma membrane vesicles
[20].
While the ¢nding that the quantity of bilirubin
taken up at 4‡C is less than the amount taken up
at 25‡C supports a potential role for speci¢c plasma
membrane transporters (which are inhibited at low
temperatures) in the cellular uptake of bilirubin, the
relatively modest reduction in Vmax at 4‡C and the
Fig. 3. Lineweaver-Burk plot of bilirubin uptake. The initial uptake velocity of BSA-bound [3H]bilirubin IXK by HepG2 monolayers
was measured over a range of bilirubin concentrations (0.9^18.5 WM), with the BSA concentration maintained at 18.5 WM. Data
points re£ect the mean þ S.D. of three separate experiments performed at 25‡C (circles) and 4‡C (squares). Based on linear regression
analyses (solid lines) of these double reciprocal plots, the Km and Vmax for albumin-bound bilirubin uptake are 4.2 þ 0.5 WM and
469 þ 41 pmol min31 mg31 ( þ S.E.M.) at 25‡C (r2 = 0.998), and 7.0 þ 0.8 WM and 282 þ 26 pmol min31 mg31 at 4‡C (r2 = 0.999). The
inset displays a reciprocal plot of the initial uptake rate versus the free bilirubin concentration, from which the Km and Vmax are cal-
culated to be 7.9 þ 1.2 nM and 396 þ 44 pmol min31 mg31 at 25‡C (r2 = 0.998), and 11.9 þ 0.8 nM and 219 þ 12 pmol min31 mg31 at
4‡C (r2 = 0.999), respectively.
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lack of a signi¢cant e¡ect of temperature on Km is
atypical for protein-mediated transport [6]. Alterna-
tively, our data can be explained by a relative de-
crease in the intracellular binding (or increase in
the albumin binding) of bilirubin at 4‡C, with the
change in Vmax re£ecting the e¡ect of temperature
on the dissociation of bilirubin from BSA. Regard-
less, our results suggest that transmembrane di¡usion
accounts for well over one-half of the UCB taken up
by HepG2 cells.
3.2. Bilirubin transport across erythrocyte plasma
membranes
It has been argued that the rapid transport of bi-
lirubin by hepatocytes, in the absence of demonstra-
ble uptake by erythrocytes, supports the existence of
speci¢c bilirubin transporters in liver cells [35,36]. In
an attempt to corroborate this assertion, we exam-
ined the transmembrane di¡usion of UCB across
model phospholipid vesicles and isolated white (he-
moglobin-deplete) erythrocyte ghosts. The equilibra-
tion of bilirubin between small unilamellar phospha-
tidylcholine donor vesicles and cbBSA was measured
over a range of donor:acceptor concentrations, and
the ¢rst-order rate constants plotted against the
phospholipid:cbBSA molar ratio (Fig. 4). At low
ratios of phospholipid:BSA, the equilibration rate
(R) approaches the £ip-£op rate constant, which is
calculated to be 1.5 þ 0.1 s31 ( þ S.E.M.) based on the
best ¢t of the data to Eq. 2. This value for kff is
lower than originally obtained using donor vesicles
labeled with £uorescent phospholipids [11], a discrep-
ancy which most likely re£ects limitations in the
present experimental system resulting from the di-
minished amplitude of the £uorescence signal at
high cbBSA concentrations (Fig. 4, inset). At high
phospholipid:BSA ratios, R asymptotically ap-
proaches 0.17 þ 0.03 s31, which correlates closely
with values previously determined for kBSAoff [11,14].
Employing a similar experimental approach, we ex-
amined bilirubin £ip-£op in isolated erythrocyte
ghosts (Fig. 5). We found that UCB is able to readily
Fig. 4. In£uence of the phospholipid:albumin molar ratio on
the rate of bilirubin equilibration. The rate of equilibration of
UCB (2 WM) between small unilamellar phosphatidylcholine
vesicles and cbBSA was measured at 25‡C over a range of
phospholipid (PL) and albumin concentrations. The ¢rst-order
rate constant is plotted against the molar ratio of phospholipid:
albumin, with each point re£ecting the mean of ¢ve stopped-
£ow injections. The curve (solid line) is generated from best-¢t
parameters for Eq. 2 (P6 0.0005): kff = 1.5 þ 0.1 s31,
kBSAoff = 0.17 þ 0.03 s
31, KBSAa /K
V
a = 64 þ 23 ( þ S.E.M.). The inset
displays £uorescence recordings of bilirubin equilibration be-
tween phosphatidylcholine vesicles (1 mM phospholipid) and in-
creasing concentrations of cbBSA (2^50 WM) obtained at 200
ms intervals. Each curve re£ects the average of six stopped-£ow
injections and is expressed as the ratio of the £uorescence inten-
sity versus the initial £uorescence at time 0.
Fig. 5. Bilirubin transmembrane di¡usion in erythrocyte ghosts.
The rate of bilirubin di¡usion across erythrocyte plasma mem-
branes was determined by examining the equilibration of UCB
(2 WM) between white (hemoglobin-deplete) erythrocyte ghosts
(100 WM phospholipid) and free cbBSA (10 WM). A representa-
tive £uorescence tracing is presented, which re£ects the average
of ¢ve stopped-£ow injections performed at 25‡C. In the inset,
the ¢rst-order rate constant for bilirubin £ip-£op was found to
be similar to that measured in small unilamellar phosphatidyl-
choline vesicles at equivalent phospholipid and cbBSA concen-
trations. Each bar represents the mean þ S.D. of three sets of
experiments.
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di¡use through erythrocyte plasma membranes at a
rate which is comparable to unilamellar phosphati-
dylcholine vesicles (Fig. 5, inset), indicating that bi-
lirubin £ip-£op is not unique to hepatocyte mem-
branes.
3.3. E¡ect of pH on the kinetics of bilirubin £ip-£op
We have previously demonstrated that bilirubin
di¡uses across phospholipid bilayers as the un-
charged diacid [11]. Based on this mechanism, it is
anticipated that bilirubin transmembrane £ip-£op
will be facilitated at low pH. We examined the e¡ect
of pH on bilirubin £ip-£op kinetics by studying the
equilibration of bilirubin between small unilamellar
phosphatidylcholine vesicles and cbBSA over a pH
range of 5^10 (Fig. 6). Surprisingly, the rate of bili-
rubin equilibration was found to increase in a sigmoi-
dal fashion with increasing pH (Fig. 6, inset). To
elucidate the mechanism whereby the hydrogen ion
concentration of the medium in£uences the £ip-£op
rate, we examined the e¡ect of pH on bilirubin equil-
ibration between small unilamellar phosphatidylcho-
line vesicles and cbBSA over a range of cbBSA con-
centrations (Fig. 7). We found that the equilibration
rate constants at pH 7.4 and 9.0 converge at the
Fig. 6. E¡ect of pH on bilirubin equilibration. The e¡ect of hy-
drogen ion concentration on the rate of UCB (2 WM) equilibra-
tion between small unilamellar phosphatidylcholine vesicles (1
mM phospholipid) and cbBSA (20 WM) was determined over a
pH range of 5^10. Each curve represents the average of 10
stopped-£ow injections performed at 25‡C. In the inset, the rate
constant for bilirubin transmembrane £ip-£op is plotted versus
pH, and ¢tted to a sigmoidal function (solid line). An in£ection
point is identi¢ed at pH 8.1.
Fig. 7. In£uence of pH on the kinetics of bilirubin equilibra-
tion. The equilibration of UCB (2 WM) between small unilamel-
lar phosphatidylcholine vesicles (1 mM phospholipid) and
cbBSA (0^10 WM) was measured at both pH 7.4 and pH 9.0,
and rate constants plotted as a function of the ratio of phos-
pholipid (PL) to cbBSA. Each point re£ects the average of six
stopped-£ow injections, with the solid lines generated by ¢tting
the data to Eq. 2.
Fig. 8. Bilirubin dissociation from cbBSA: e¡ect of pH. The
rate of dissociation of UCB (1 WM) from cbBSA (1 WM) was
measured using stopped-£ow techniques. The reemergence of
Cascade blue £uorescence re£ects bilirubin transfer from cbBSA
to a large molar excess of acceptor phosphatidylcholine vesicles
(1 mM phospholipid). Each curve represents the average of ¢ve
stopped-£ow injections and is normalized to a scale of 0^1. Bi-
lirubin dissociation from cbBSA is faster at pH 9.0 as com-
pared with pH 7.4, with ¢rst-order rate constants of
0.132 þ 0.003 s31 and 0.060 þ 0.001 s31 ( þ S.E.M.), respectively.
As shown in the inset, the dissociation rate constant at pH 6.0
(0.0076 þ 0.0001 s31) is over an order of magnitude slower than
at pH 9.0.
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y-intercept, suggesting that pH has a relatively mod-
est e¡ect on kff . In contrast, the value for kBSAoff is
nearly two times greater at pH 9.0 as compared
with pH 7.4, indicating that the rate of bilirubin
solvation from cbBSA decreases with increasing hy-
drogen ion concentration. This hypothesis was veri-
¢ed by directly examining the e¡ect of pH on bili-
rubin dissociation from cbBSA (Fig. 8). Based on
these ¢ndings, it appears that the e¡ect of pH on
the bilirubin equilibration rate is due, at least in
part, to enhanced dissociation of bilirubin from
cbBSA at low hydrogen ion concentrations.
Bilirubin IXK and other open-chain tetrapyrrole
monomers exhibit a propensity to self-associate (ag-
gregate) in aqueous solution [37]. At alkaline pH,
aggregation is limited to the formation of reversible
and thermodynamically stable dimeric complexes;
however, at pH values below 8.3, self-association of
bilirubin is characterized by the irreversible forma-
tion of insoluble, metastable colloids [38]. In order
to determine whether the decline in the equilibration
rate with decreasing pH might be attributable to bil-
irubin aggregation, we examined the e¡ect of a pH
jump on bilirubin equilibration between phosphati-
dylcholine vesicles and cbBSA. A suspension of small
unilamellar vesicles were prepared at pH 6.0, loaded
with bilirubin, and rapidly injected into a solution of
cbBSA also bu¡ered at pH 6.0 (Fig. 9A). As previ-
ously observed (Fig. 6), a slow decline in Cascade
blue £uorescence is observed. Abruptly increasing
the external pH to 9.0 with potassium hydroxide
produces a sharp diminution in £uorescence, which
remains una¡ected by the further addition of enough
nigericin (a proton/potassium ionophore) to com-
pletely collapse the pH gradient across the vesicle
bilayer [11]. Since self-association of bilirubin mono-
mers is irreversible at pH 6.0, aggregation should
manifest as loss of the £ip-£op signal. The rapid re-
storation of an equilibration curve following an in-
crease in the pH of the external medium suggests
that the slow equilibration rate observed at high hy-
drogen ion concentrations is not the result of bili-
rubin aggregation.
To further examine whether the pH internal to the
vesicle controls the rate of bilirubin equilibration,
bilirubin-incorporated vesicles were prepared at pH
9.0, and the external pH adjusted to 6.0 by abrupt
dilution in a bu¡ered solution of cbBSA, producing
an instantaneous transmembrane pH gradient. Re-
sults similar to those observed with vesicles prepared
at pH 6.0 were obtained (Fig. 9B). The additional
¢nding that the £uorescence intensity of free cbBSA
is una¡ected by pH (Fig. 9C) con¢rms that these
Fig. 9. Bilirubin equilibration between phospholipid vesicles and
cbBSA: pH-jump analysis. (A) The e¡ect of a rapid change in
pH on UCB (2 WM) equilibration between small unilamellar
phosphatidylcholine vesicles (1 mM phospholipid) and free
cbBSA (20 WM) is shown. Vesicles were prepared in 0.1 M po-
tassium phosphate (pH 6.0), and loaded with bilirubin. At time
0, 100 Wl of the vesicle suspension was injected into 3 ml of a
stirred solution of 20 WM cbBSA in 0.1 M potassium phosphate
(pH 6.0). The pH of the medium subsequently was adjusted to
pH 9.0 by the rapid injection of a small aliquot (5 Wl) of potas-
sium hydroxide (KOH). The addition of 3 Wl (1 Wg mg31 phos-
pholipid) nigericin (NIG) caused no additional change in £uo-
rescence. (B) Similar results are obtained when bilirubin-
containing vesicles are prepared at pH 9.0 and then added to a
pH 6.0 bu¡ered potassium phosphate solution containing
cbBSA, thereby creating a transbilayer proton gradient. Addi-
tion of KOH to bring the external pH to 9.0 again induces a
rapid decline in Cascade blue £uorescence, with no further ef-
fect of nigericin. (C) No change in £uorescence intensity occurs
when a solution of cbBSA (20 WM), in the absence of vesicles
or bilirubin, is subjected to a pH jump from 6.0 to 9.0 by the
addition of KOH.
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data re£ect quenching of cbBSA by bilirubin rather
than a nonspeci¢c e¡ect of pH on Cascade blue £uo-
rescence. Based on these results, it appears that the
pH of the medium external (rather than internal) to
the vesicle is the key determinant of the bilirubin
equilibration rate, suggesting that bilirubin solvation
from the external hemilea£et of the vesicle bilayer is
rate-limiting at low pH. Indeed, direct examination
of the e¡ect of hydrogen ion concentration on bili-
rubin solvation from phosphatidylcholine vesicles re-
veals that the dissociation rate constant declines by
over ¢ve orders of magnitude as the pH is decreased
from 7.4 to 6.0 (Fig. 10). Taken together, our ¢nd-
ings indicate that the pH-dependent alterations in the
rate of bilirubin equilibration between phospholipid
vesicles and cbBSA represent the combined e¡ect of
diminished bilirubin dissociation from albumin and
from the external surface of the donor vesicles at low
pH, as opposed to a direct e¡ect of pH on bilirubin
transmembrane di¡usion.
4. Discussion
The outlined experiments were designed to exam-
ine the in£uence of serum binding proteins on the
kinetics of bilirubin uptake by HepG2 cell mono-
layers. Our prior observation that the rate of biliru-
bin transmembrane £ip-£op [11] exceeds the o¡-rate
from serum albumin [14] led to the proposition that
solvation from albumin represents the rate-limiting
step in the clearance of UCB by the liver. This hy-
pothesis is supported by our demonstration that
HepG2 cells take up HSA-bound bilirubin faster
than BSA-bound bilirubin, and that the cellular up-
take rate coincides with the rate of bilirubin dissoci-
ation from the proteins. Since the a⁄nity of HSA for
bilirubin exceeds that of BSA, the increased rate of
bilirubin uptake from HSA cannot be due to higher
free bilirubin concentrations. Taken together, these
data suggest that hepatocellular uptake of albumin-
bound bilirubin is determined by the rate of solva-
tion from the protein, consistent with the concept of
dissociation-limited uptake [13].
The fact that bilirubin uptake is limited by disso-
ciation from its carrier underlies the paradoxical ob-
servation that the bilirubin equilibration rate de-
creases with increasing hydrogen ion concentration.
We previously have shown that, at pH 7.4, the equil-
ibration of UCB between membrane vesicles and
albumin is limited by the rate of bilirubin transmem-
brane £ip-£op [11]. In the present study, we demon-
strate that the o¡-rate of bilirubin from albumin and
from phospholipid bilayers decreases with the pH of
the medium. Hence, as the pH is lowered, solvation
of bilirubin from the membrane surface becomes
rate-limiting and the equilibration rate declines,
even though the actual £ip-£op rate does not. Our
data also provide insight into the acid-base proper-
ties of bilirubin IXK, the physiologic isomer of UCB.
Based on [13C]NMR analyses [39], the pKa for mes-
obilirubin XIIIK, a structurally related bilirubin ana-
log, was estimated to be in the range of 4.2^4.9,
consistent with established pKa values for a variety
of other dicarboxylic acids. In contrast, the results of
partitioning experiments suggest that the pKa for the
carboxyl moieties of bilirubin IXK are 8.1 and 8.4
[34], ¢ndings which are highly concordant with bili-
rubin aqueous solubility [37]. Proponents of these
latter investigations have argued that the unusually
high pKa values for UCB result from the formation
Fig. 10. E¡ect of pH on bilirubin solvation from phospholipid
vesicles. The rate of bilirubin solvation from small unilamellar
phosphatidylcholine vesicles was determined by monitoring the
changes in £uorescence associated with the transfer of UCB
(0.5 WM) from 0.5 mol% dansyl-PE-labeled vesicles (100 WM
phospholipid) to unlabeled phosphatidylcholine vesicles (500
WM phospholipid). Vesicles were suspended in 0.1 M potassium
phosphate (pH 7.4) and £uorescence intensity recorded over a
time interval of 220 ms following the stopped-£ow mixing of
donor and acceptor membranes. The curve re£ects the average
of ¢ve injections conducted at 25‡C and is best described by a
single exponential function (solid line) with a ¢rst-order rate
constant of 229 þ 5 s31 ( þ S.E.M.). The inset displays the re-
sults of an identical experiment performed at pH 6.0, with the
curve re£ecting the average of three stopped-£ow injections.
The ¢rst-order rate constant of 0.0011 þ 0.0001 s31 is calculated
from a single exponential ¢t of the data (solid line). Curves are
normalized to a scale of 0^1.
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of unique intramolecular hydrogen bonds [40]. Our
pH studies indicate a transition point at pH 8.1,
providing indirect support for the presence of a
pKa value in this range.
We have demonstrated that uptake of albumin-
bound bilirubin by HepG2 cells is rapid and satura-
ble, and that the Km is compatible with normal phys-
iologic bilirubin concentrations. Both the initial rate
and the quantity of UCB taken up by HepG2 cells at
4‡C are approximately two-thirds of that measured
at 25‡C. The fact that bilirubin uptake is saturable
and temperature-dependent has been construed as
evidence for the existence of a speci¢c membrane
transporter(s) [20]. Since two putative bilirubin trans-
port proteins, BSP/bilirubin binding protein (BBBP)
and bilitranslocase, are expressed by HepG2 cells
[6,41], there exists the possibility that these proteins
facilitate bilirubin uptake in this cell line. Indeed, this
hypothesis ¢ts nicely with data demonstrating that
pretreatment of HepG2 monolayers or isolated hep-
atocyte cultures with antibodies to BBBP decreases
the cellular uptake of UCB by 30^40% [4,6].
On the other hand, di¡usional processes also have
been shown to exhibit ‘saturation’ kinetics [42,43].
Furthermore, while it is reasonable to conclude
that uptake at 4‡C is di¡usional in nature (since pro-
tein-mediated transport typically is negligible at this
temperature), the converse assumption, that in-
creased bilirubin uptake observed at higher temper-
atures re£ects the additional activity of a transporter,
is not necessarily valid. Indeed, our data suggest that
simple di¡usion cannot be distinguished from pro-
tein-mediated uptake using an experimental ap-
proach where albumin serves as the bilirubin donor.
This is because the measured uptake rate re£ects bil-
irubin dissociation from human (or bovine) serum
albumin which, at 25‡C, is over ¢ve-fold (50-fold)
slower than transmembrane transport [11]. Hence,
the increase in Vmax observed at 25‡C as compared
with 4‡C can be readily explained by the more rapid
dissociation of bilirubin from albumin at higher tem-
peratures [14]. This hypothesis is supported by the
observation that the rate of cellular uptake for albu-
min-bound bilirubin corresponds closely with the bi-
lirubin o¡-rate from albumin at both 4‡C and 25‡C.
Moreover, the relatively modest decrease in Km at
higher temperatures is less than would be expected
if transport was protein-mediated. The ¢nding that
substantial uptake of UCB occurs at 4‡C, represent-
ing 60^70% of total uptake at 25‡C, provides addi-
tional support for a non-speci¢c di¡usional uptake
mechanism [7,11,21]. While our results do not ex-
clude a contribution of speci¢c membrane transport-
ers, they do suggest that hepatocellular bilirubin up-
take occurs principally by transmembrane di¡usion;
thereby providing an explanation for the di¡use yel-
low staining observed in a wide variety of tissues in
patients with hyperbilirubinemia [44,45]. Indeed, de-
spite reports to the contrary [35,36], our analyses
indicate that red cell membranes are freely permeable
to UCB, consistent with the original observations of
Wennberg [7].
The proposition that a signi¢cant proportion of
cellular bilirubin uptake occurs by passive di¡usion
is supported by the ¢ndings of a number of investi-
gators. For example, nonspeci¢c uptake, as de¢ned
by the absence of saturation [21], non-antibody in-
hibitable uptake [4], uptake by non-transfected con-
trol cells [46], or cellular uptake at 4‡C [20], repre-
sents a sizeable proportion of total cellular bilirubin
uptake in most in vitro transport studies. It has fur-
ther been shown that UCB is able to rapidly di¡use
through model phospholipid vesicles in the absence
of transport proteins [9,11,47,48], and that phospho-
lipid acyl saturation, lipid packing, and cholesterol
concentration have little impact on bilirubin £ip-£op
kinetics [11]. Both free and BSA-bound UCB are
taken up by HeLa cells [46], which do not express
any of the putative bilirubin transport proteins.
Moreover, at physiologic bilirubin concentrations,
Gunn rat ¢broblasts transduced to express UDP-glu-
curonosyltransferase activity are able to conjugate
bilirubin at a rate equivalent to that of normal hep-
atocytes [30], implying e⁄cient uptake of UCB. Fi-
nally, data regarding the biliary excretion of various
bilirubin analogs by normal versus Gunn rats [49]
provide additional in vivo support for a di¡usional
mechanism of bilirubin transport into the hepato-
cyte. In conjunction with the present studies, these
observations provide ample support for the hypoth-
esis that a substantial component of bilirubin uptake
occurs via transmembrane di¡usion. Precise delinea-
tion of the role that transport-proteins play in the
uptake of UCB await the results of cloning and func-
tional expression studies.
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